Allos third one fourth net loss decreases to $11.

As of September 30, 2011, the Company had no debts and $100.4 million in total cash, cash equivalents and investments. ‘We believe our achievement of significant year-over-year revenue development reflects increased disease-state awareness and brand awareness of FOLOTYN for sufferers with relapsed or refractory peripheral T-cell lymphoma, for whom there remains an unmet need,’ commented Paul L. Berns, president and chief executive officer of Allos Therapeutics. ‘We ended the 3rd quarter with a solid balance sheet and remain centered on growing U.S. Product sales of FOLOTYN for relapsed or refractory PTCL while prudently managing our working expenses.The researchers would ultimately like to see healthful eating promoted through advergames. ‘We hope that people can translate the use of engaging entertaining on the web tactics like this to teach healthy eating and various other healthy lifestyle behaviors to children,’ Quilliam said. The article, ‘Consistency of Diet Recommendations for Foods Marketed to Children in the usa,’ was published in a recent issue of the journal Preventing Chronic Disease, along with a podcast interview with the authors.. ASU, Banner Wellness form new analysis alliance to advance treatment for neurodegenerative diseases Arizona State University and Banner Wellness today announced a new research alliance to progress the scientific study, treatment and prevention of Alzheimer's, Parkinson's and other neurodegenerative diseases.